Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
November 03, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investment Conferences

NEWARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 01, 2022 08:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development

NEWARK, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 03, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022

NEWARK, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
September 14, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Hosting Virtual Analyst Day on September 22

Redefining Expectations for PBC Patients September 22, 2022 at 10:30 AM ET NEWARK, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage...
September 06, 2022 08:02 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

NEWARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
August 24, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022

NEWARK, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
August 11, 2022 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update

Enrollment completed in RESPONSE with 193 patients enrolled in over 20 countries Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) --...
August 04, 2022 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
August 01, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

NEWARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right